JP6832923B2 - ブロモドメイン阻害薬としての２−オキソ−１，２−ジヒドロピリジン−３，５−ジカルボキサミド化合物 - Google Patents
ブロモドメイン阻害薬としての２−オキソ−１，２−ジヒドロピリジン−３，５−ジカルボキサミド化合物 Download PDFInfo
- Publication number
- JP6832923B2 JP6832923B2 JP2018517320A JP2018517320A JP6832923B2 JP 6832923 B2 JP6832923 B2 JP 6832923B2 JP 2018517320 A JP2018517320 A JP 2018517320A JP 2018517320 A JP2018517320 A JP 2018517320A JP 6832923 B2 JP6832923 B2 JP 6832923B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- dihydropyridine
- dicarboxamide
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 COC(C1=CC(Br)=CN(C(*)*)C1=O)OC Chemical compound COC(C1=CC(Br)=CN(C(*)*)C1=O)OC 0.000 description 6
- IQBVYZUOXFKSGT-UHFFFAOYSA-N CCCCOC(C(C=C1C(NC)=O)=CN(Cc2cccc(C)c2F)C1=O)=O Chemical compound CCCCOC(C(C=C1C(NC)=O)=CN(Cc2cccc(C)c2F)C1=O)=O IQBVYZUOXFKSGT-UHFFFAOYSA-N 0.000 description 1
- SDPVKAGJYCRGDD-UHFFFAOYSA-N CNC(C1=CC(Br)=CN(Cc2ccccc2)C1=O)=O Chemical compound CNC(C1=CC(Br)=CN(Cc2ccccc2)C1=O)=O SDPVKAGJYCRGDD-UHFFFAOYSA-N 0.000 description 1
- STZDNDKVRQFUIU-UHFFFAOYSA-N COC(C1=CC=C[U]C1=O)=O Chemical compound COC(C1=CC=C[U]C1=O)=O STZDNDKVRQFUIU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237002P | 2015-10-05 | 2015-10-05 | |
| US62/237,002 | 2015-10-05 | ||
| PCT/EP2016/073532 WO2017060180A1 (en) | 2015-10-05 | 2016-10-03 | 2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529737A JP2018529737A (ja) | 2018-10-11 |
| JP2018529737A5 JP2018529737A5 (enExample) | 2019-11-07 |
| JP6832923B2 true JP6832923B2 (ja) | 2021-02-24 |
Family
ID=57113320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517320A Expired - Fee Related JP6832923B2 (ja) | 2015-10-05 | 2016-10-03 | ブロモドメイン阻害薬としての２−オキソ−１，２−ジヒドロピリジン−３，５−ジカルボキサミド化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10471050B2 (enExample) |
| EP (1) | EP3359531B1 (enExample) |
| JP (1) | JP6832923B2 (enExample) |
| KR (1) | KR20180059551A (enExample) |
| CN (1) | CN108290866B (enExample) |
| AU (1) | AU2016334637A1 (enExample) |
| BR (1) | BR112018006545A2 (enExample) |
| CA (1) | CA2999379A1 (enExample) |
| ES (1) | ES2831322T3 (enExample) |
| RU (1) | RU2018114705A (enExample) |
| WO (1) | WO2017060180A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43940A (fr) | 2015-09-02 | 2018-12-12 | Glaxosmithkline Ip No 2 Ltd | Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine |
| EP3353162A1 (en) | 2015-09-22 | 2018-08-01 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| BR112018006545A2 (pt) | 2015-10-05 | 2018-10-16 | Glaxosmithkline Ip No 2 Ltd | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? |
| ES2840848T3 (es) | 2016-04-07 | 2021-07-07 | Glaxosmithkline Ip No 2 Ltd | Derivados de piridilo como inhibidores de bromodominio |
| KR20190006567A (ko) * | 2016-05-24 | 2019-01-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 브로모도메인 억제제로서의 피리딘 디카르복사미드 유도체 |
| GB201703282D0 (en) | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
| JOP20190192A1 (ar) | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| GB201814167D0 (en) | 2018-08-31 | 2018-10-17 | Glaxosmithkline Ip No 2 Ltd | Compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60139506D1 (de) | 2000-12-28 | 2009-09-17 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| WO2003070277A1 (en) * | 2002-02-19 | 2003-08-28 | Shionogi & Co., Ltd. | Antipruritics |
| CA2542007C (en) | 2002-10-09 | 2010-06-29 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| EP1433788A1 (en) | 2002-12-23 | 2004-06-30 | Aventis Pharma Deutschland GmbH | Pyrazole-derivatives as factor Xa inhibitors |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AU2013341200A1 (en) | 2012-11-08 | 2015-07-02 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| MA43940A (fr) | 2015-09-02 | 2018-12-12 | Glaxosmithkline Ip No 2 Ltd | Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine |
| BR112018006545A2 (pt) | 2015-10-05 | 2018-10-16 | Glaxosmithkline Ip No 2 Ltd | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? |
| ES2840848T3 (es) | 2016-04-07 | 2021-07-07 | Glaxosmithkline Ip No 2 Ltd | Derivados de piridilo como inhibidores de bromodominio |
| KR20190006567A (ko) | 2016-05-24 | 2019-01-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 브로모도메인 억제제로서의 피리딘 디카르복사미드 유도체 |
-
2016
- 2016-10-03 BR BR112018006545A patent/BR112018006545A2/pt active Search and Examination
- 2016-10-03 ES ES16778310T patent/ES2831322T3/es active Active
- 2016-10-03 JP JP2018517320A patent/JP6832923B2/ja not_active Expired - Fee Related
- 2016-10-03 CA CA2999379A patent/CA2999379A1/en not_active Abandoned
- 2016-10-03 EP EP16778310.9A patent/EP3359531B1/en active Active
- 2016-10-03 KR KR1020187012923A patent/KR20180059551A/ko not_active Withdrawn
- 2016-10-03 CN CN201680071214.5A patent/CN108290866B/zh not_active Expired - Fee Related
- 2016-10-03 US US15/766,222 patent/US10471050B2/en not_active Expired - Fee Related
- 2016-10-03 AU AU2016334637A patent/AU2016334637A1/en not_active Abandoned
- 2016-10-03 RU RU2018114705A patent/RU2018114705A/ru not_active Application Discontinuation
- 2016-10-03 WO PCT/EP2016/073532 patent/WO2017060180A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20180280368A1 (en) | 2018-10-04 |
| EP3359531B1 (en) | 2020-08-19 |
| WO2017060180A1 (en) | 2017-04-13 |
| BR112018006545A2 (pt) | 2018-10-16 |
| EP3359531A1 (en) | 2018-08-15 |
| RU2018114705A (ru) | 2019-11-07 |
| US10471050B2 (en) | 2019-11-12 |
| CN108290866B (zh) | 2020-12-18 |
| AU2016334637A1 (en) | 2018-04-12 |
| JP2018529737A (ja) | 2018-10-11 |
| ES2831322T3 (es) | 2021-06-08 |
| CN108290866A (zh) | 2018-07-17 |
| KR20180059551A (ko) | 2018-06-04 |
| CA2999379A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6795588B2 (ja) | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド | |
| CN108137542B (zh) | 用作溴结构域抑制剂的吡啶酮二甲酰胺 | |
| JP2018529737A (ja) | ブロモドメイン阻害薬としての２−オキソ−１，２−ジヒドロピリジン−３，５−ジカルボキサミド化合物 | |
| JP6885968B2 (ja) | ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体 | |
| JP6954921B2 (ja) | ブロモドメイン阻害薬としてのピリジル誘導体 | |
| JP6857254B2 (ja) | ブロモドメイン阻害薬としてのピラゾール誘導体 | |
| EP3589615B1 (en) | Pyridyl derivatives as bromodomain inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190920 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190920 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6832923 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |